Table 4.
Number of cancer cases in subjects with residence in the Schiphol area according to site, gender and area of residence, 1988–2003
| cancer site (ICD-10 code) and gender | area of residence | |||||||
| ring zone | core zone | |||||||
| parameter | parameter | |||||||
| number of cases | SIR# | 95% CI | number of cases | SIR# | 95% CI | RR## | 95% CI | |
| All malignancies (C00–C95) | 10 855 | 1.01 | 0.99, 1.03 | 2 352 | 1.06* | 1.02, 1.10 | 1.05* | 1.01, 1.10 |
| adult males | 5 440 | 0.98 | 0.96, 1.01 | 1 257 | 1.07 | 1.01, 1.13 | 1.09* | 1.03, 1.16 |
| adult females | 5 356 | 1.03 | 1.00, 1.06 | 1 080 | 1.04 | 0.98, 1.11 | 1.01 | 0.95, 1.08 |
| children (<15) | 59 | 1.25 | 0.95, 1.61 | 15 | 1.29 | 0.72, 2.13 | 1.04 | 0.59, 1.83 |
| Head & neck (C00–C14) | 238 | 1.06 | 0.93, 1.21 | 44 | 0.90 | 0.65, 1.21 | 0.85 | 0.61, 1.17 |
| males | 133 | 0.92 | 0.77, 1.09 | 29 | 0.89 | 0.59, 1.27 | 0.96 | 0.64, 1.44 |
| females | 105 | 1.32* | 1.08, 1.59 | 15 | 0.93 | 0.52, 1.53 | 0.70 | 0.41, 1.21 |
| Gastrointestinal tract (C15–C26) | 2 422 | 0.99 | 0.95, 1.03 | 467 | 0.96 | 0.87, 1.05 | 0.97 | 0.88, 1.07 |
| males | 1 240 | 0.98 | 0.92, 1.03 | 254 | 0.95 | 0.83, 1.07 | 0.97 | 0.85, 1.11 |
| females | 1 182 | 1.00 | 0.95, 1.06 | 213 | 0.97 | 0.85, 1.11 | 0.97 | 0.84, 1.12 |
| Respiratory system (C30–C34) | 1 484 | 0.91* | 0.86, 0.96 | 378 | 1.10 | 0.99, 1.22 | 1.21* | 1.08, 1.35 |
| males | 1 085 | 0.85* | 0.80, 0.90 | 293 | 1.08 | 0.96, 1.21 | 1.27* | 1.12, 1.45 |
| females | 399 | 1.13* | 1.02, 1.24 | 85 | 1.17 | 0.93, 1.44 | 1.04 | 0.82, 1.31 |
| Breast (C50) | 1 731 | 1.05* | 1.01, 1.11 | 356 | 1.04 | 0.93, 1.15 | 0.99 | 0.88, 1.11 |
| Female genital organs (C51–C58) | 567 | 0.93 | 0.86, 1.01 | 143 | 1.16 | 0.98, 1.37 | 1.24* | 1.04, 1.50 |
| Prostate (C61) | 1 044 | 1.02 | 0.96, 1.08 | 247 | 1.19* | 1.05, 1.35 | 1.17* | 1.02, 1.34 |
| Bladder & other urinary tract (C65–C68) | 468 | 1.09 | 0.99, 1.19 | 102 | 1.18 | 0.96, 1.43 | 1.16 | 0.93, 1.43 |
| males | 341 | 1.05 | 0.95, 1.17 | 84 | 1.26* | 1.01, 1.56 | 1.20 | 0.94, 1.52 |
| females | 100 | 0.93 | 0.76, 1.13 | 18 | 0.92 | 0.54, 1.44 | 0.98 | 0.60, 1.63 |
| Hematological malignancies (C81–C96) | 855 | 1.10* | 1.03, 1.18 | 189 | 1.17* | 1.01, 1.35 | 1.06 | 0.91, 1.24 |
| males | 483 | 1.16* | 1.06, 1.27 | 115 | 1.26* | 1.04, 1.51 | 1.09 | 0.89, 1.33 |
| females | 372 | 1.04 | 0.94, 1.15 | 74 | 1.06 | 0.83, 1.33 | 1.02 | 0.79, 1.31 |
| Other sites | 2 073 | 1.03 | 0.99, 1.08 | 426 | 1.02 | 0.93, 1.12 | 0.99 | 0.89, 1.10 |
| males | 1 148 | 1.03 | 0.97, 1.09 | 243 | 1.01 | 0.89, 1.14 | 0.98 | 0.85, 1.12 |
| females | 925 | 1.03 | 0.97, 1.10 | 183 | 1.04 | 0.90, 1.20 | 1.01 | 0.86, 1.18 |
* p < 0.05
# reference population: the Netherlands 1989–2003
## ratio of the SIR of the core zone and the SIR of the ring zone
CI = confidence interval; SIR = standardized incidence ratio; RR = rate ratio